U.S. Advisory Panel to Vote on Delaying Newborn Hepatitis B Vaccine

On December 2, the chair of a Health Secretary appointed vaccine advisory committee announced that the panel would vote later in the week on whether to recommend delaying hepatitis B vaccination for most newborns in the United States. The proposal, which would alter a decades long routine, comes as Health Secretary Robert F. Kennedy Jr. pursues broader changes to national vaccination policy.

Details of any proposed delay were not finalized, the chair said, leaving open how long the vaccination would be postponed and which newborns would be affected. The committee is scheduled to consider the measure this week and could offer formal recommendations that would influence federal guidance and hospital practices.

Public health officials and researchers have long endorsed the practice of administering the hepatitis B vaccine soon after birth. Evaluations carried out over the past decades have found that the birth dose helped cut child infections by more than 95 percent, a reduction that public health authorities attribute to preventing mother to child transmission and protecting infants before they can complete the full vaccine series.

The prospect of changing that routine has raised concern among infectious disease experts and pediatric organizations, who say delaying the birth dose could leave infants vulnerable during a critical window. Advocates of maintaining the current schedule point to the strength of the historical evidence and the long record of preventing perinatal transmission, particularly in cases where maternal infection status is unknown or screening is incomplete.

Supporters of the proposed change argue that delaying the vaccine for many newborns could allow for more targeted administration based on maternal risk factors or laboratory screening results. Proponents contend that modern prenatal screening and changes in the epidemiology of hepatitis B may alter the balance of benefits and risks for a universal birth dose policy. The committee chair said those and other considerations would be part of the upcoming deliberations, but did not provide specifics on which populations might be excluded or how screening practices would be integrated.

A vote by the advisory committee would not by itself change clinical practice, but it could prompt the Centers for Disease Control and Prevention and other federal agencies to revise official immunization schedules and hospital protocols. Any shift in policy would carry logistical and ethical implications, including the need to ensure that pregnant people receive timely screening and that infants who remain at risk are identified and vaccinated without delay.

The debate highlights broader tensions over how to weigh long standing public health interventions against new policy priorities and changing scientific assessments. With the committee set to vote this week, health systems, clinicians and families will be watching for guidance that could reshape the first hours of newborn care across the country.